Shots:

• Evotec will take care of medicinal chemistry- in vitro and in vivo pharmacology plus its development capabilities and expertise while Celmatix will utilize its novel drug target discovery based on its multi-omics Reproductive Atlas platform
• The focus of the agreement is to combine Celmatix database and expertise with Evotec’s footprints in therapeutic discovery with the focus of developing pre-clinical candidates for women’s reproductive health- including polycystic ovary syndrome (“PCOS”)- endometriosis- and infertility
• Celamtix’s Reproductive Atlas platform is a database enabled with biological annotations refined from the peer-reviewed literature with genomic data linked to data about lifestyle- diet- environment- and reproductive outcomes and has launched its first study with the BioMe BioBank Program of the Charles Bronfman Institute for Personalized Medicine

Click here to­ read full press release/ article | Ref: Evotec | Image: Twitter